A sample size computation method for non-linear mixed effects models with applications to pharmacokinetics models

Statistics in Medicine

Volumn 23, Issue 16, 2004, Pages 2551-2566

  Kang, Dongwoo ^a   Schwartz, Janice B ^b   Verotta, Davide ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Mixed effects model; Population pharmacodynamics; Population pharmacokinetics; Sample size; Wald statistic

Indexed keywords

NIFEDIPINE;

ANALYTIC METHOD; ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; EXPERIMENTAL DESIGN; HUMAN; LINEAR SYSTEM; MATHEMATICAL ANALYSIS; MONTE CARLO METHOD; NONLINEAR SYSTEM; PHARMACOLOGICAL PARAMETERS; POPULATION RESEARCH; SAMPLE SIZE; STATISTICAL ANALYSIS; STATISTICAL MODEL;

AFRICAN CONTINENTAL ANCESTRY GROUP; CALCIUM CHANNEL BLOCKERS; COMPUTER SIMULATION; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; MODELS, BIOLOGICAL; MODELS, STATISTICAL; MONTE CARLO METHOD; NIFEDIPINE; PHARMACOKINETICS; SAMPLE SIZE;

EID: 4344613538     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/sim.1695     Document Type: Article

References (27)

1. Rowland M, Tozer TN. Clinical Pharmacokinetics: Concepts and Applications (3rd edn). Lippincott Williams & Wilkins: Media, PA, 1995.
2. Cohen J. The statistical power of abnormal-social psychological research: a review. Journal of Abnormal and Social Psychology 1962; 65:145-153.
3. Freiman JA, Chalmers TC, Smith H, Kuebler RR. The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial: survey of 71 'negative' trials. The New England Journal of Medicine 1978; 299:690-694.
4. Rochon J. Application of GEE procedures for sample size calculations in repeated measures experiments. Statistics in Medicine 1998; 17:1643-1658.
5. Vonesh EF, Schork MA. Sample sizes in the multivariate analysis of repeated measurements. Biometrics 1986; 42:601-610.
6. Cohen J. Statistical Power Analysis for the Behavioral Sciences (2nd edn). Lawrence Erlbaum Associates, Publishers: Hillsdale, NJ, 1988.
7. Lui K-J. Sample sizes for repeated measurements in dichotomous data. Statistics in Medicine 1991; 10: 463-472.
8. Lui K-J, Cumberland WG. Sample size requirement for repeated measurements in continuous data. Statistics in Medicine 1992; 11:633-641.
9. Lui K-J. Sample size determination for repeated measurements in bioequivalence test. Journal of Pharmacokinetics and Biopharmaceutics 1997; 25(4):507-513.
10. Chow S-C, Wang H. On sample size calculation in bioequivalence trials. Journal of Pharmacokinetics and Biopharmaceutics 2001; 28:155-169.
11. Davidian M, Giltinan DM. Nonlinear Models for Repeated Measurement Data. Chapman & Hall: Englewood Cliffs, NJ, 1995.
12. Pharsight Trial Simulator. Pharsight.
13. Bloch DA. Sample size requirements and the cost of a randomized clinical trial with repeated measurements. Statistics in Medicine 1986; 5:663-667.
14. Muller KE, LaVange LM, Ramey SL, Ramey CT. Power calculations for general linear multivariate models including repeated measures applications. Journal of the American Statistical Association 1992; 87(420): 1209-1226.
15. Kupper LL, Hafner KB. How appropriate are popular sample size formulas? The American Statistician 1989; 43:101-105.
16. Liang K-Y, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986; 73:13-22.
17. Wald A. Tests of statistical hypotheses concerning several parameters when the number of observations is large. Transactions of the American Mathematical Society 1943; 54:426-482.
18. Beal S, Sheiner LB. NONMEM Users Guide. NONMEM Project Group, University of California San Francisco: San Francisco, 1991.
19. Lindstrom MJ, Bates DM. Nonlinear mixed effects models for repeated measures data. Biometrics 1990; 46: 673-687.
20. SAS. SAS Institute Inc.
21. S-PLUS Reference Manual. Statistical Sciences, Inc.
22. Fedorov VV. Theory of Optimal Experiments. Academic Press: New York, 1972.
23. D'Argenio DZ, Schumitzky A. ADAPT II User's Guide: Pharmacokinetic/Pharmacodynamic Systems Analysis Software. Biomedical Simulations Resource, University of Southern California: Los Angeles, 1997.
24. Krecic-Shepard ME, Park K, Barnas C, Slimko J, Kerwin DR, Schwartz JB. Race and sex influence clearance of nifedipine: Results of a population study. Clinical Pharmacology and Therapeutics 2000; 68:130-142.
25. Walter E, Pronzato L. Optimal experiment design for nonlinear models subject to large prior uncertainties. American Journal of Physiology 1987; 253:R530-R534.
26. Walter E, Pronzato L. Robust Experiment Design: Between Qualitative and Quantitative. Pergamon Press: Oxford, 1987.
27. Tod M, Mentre M, Merle F, Mallet Y. A robust optimal design for the estimation of hyperparameters in population pharmacokinetics. Journal of Pharmacokinetics and Biopharmaceutics 1998; 26:689-716.